SpringWorks Therapeutics Q2 2024 GAAP EPS $(0.54) Beats $(1.13) Estimate, Sales $59.733M Beat $34.343M Estimate
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics (NASDAQ:SWTX) reported Q2 2024 GAAP EPS of $(0.54), significantly beating the analyst estimate of $(1.13). The company also reported sales of $59.733 million, surpassing the estimate of $34.343 million.
August 07, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SpringWorks Therapeutics reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.54) beating the $(1.13) estimate and sales of $59.733 million beating the $34.343 million estimate.
The significant beat on both EPS and sales estimates is likely to positively impact the stock price in the short term. Investors will view the better-than-expected performance as a strong indicator of the company's financial health and growth potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100